To receive the Femtech World newsletter, sign up here.
News
‘No more cute mentorship programmes’: femtech community reacts to Women’s Health Strategy
Femtech entrepreneurs have expressed concerns over the government’s lack of clarity around the 10-year strategy
Women in the femtech community have reacted to England’s Women’s Health Strategy, amid fears that the government could be using the initiative as a “short-term vote-winner”.
Femtech entrepreneurs have asked for more innovation support, warning that a failure to provide enough funding could hamper the ambitions of the strategy.
The women have told Femtech World that the UK government should be held accountable to ensure its commitment to tackling health inequalities goes beyond “mere election-year rhetoric”.
The Women’s Health Strategy, developed and published in 2022, aims to address longstanding gaps in the health and care system.
The initiative seeks to improve care for menstrual and gynaecological conditions, expand women’s health hubs and accelerate research.
While many women’s health organisations have welcomed the plan, women in the femtech community have raised concerns about the government’s lack of clarity.
“It’s good to see the government prioritising women on their agenda, but I don’t see specific numbers,” Hélène Guillaume, founder and CEO of the training and nutrition app Wild AI, told Femtech World.
“One in ten women in the UK suffer from endometriosis and go undiagnosed for an average of seven and a half years. I’d like to see a commitment to reduce that to six months.
“I’d like the government to make including women in research compulsory, as 80 per cent of the medical research is still done on males – I’d like to see them pledging actual funding on this.
“We need more funding commitments to innovation. The government could and should play a role here too by investing in women. No more cute mentorship programmes, but actual cash.”
Valentina Milanova, women’s health expert and founder of the gynaecological start-up Daye, said: “It is crucial to hold Sunak’s cabinet accountable to ensure their commitment goes beyond mere election-year rhetoric.
“To significantly improve gynaecological health in the UK, the government should focus on increasing both public and private funding for innovations related to vaginal, menstrual, hormonal and reproductive health, which is currently shamefully low.
“Before Brexit, British start-ups, universities and researchers had access to funding from the European Innovation Council (EIC) through their venture capital investment scheme, which could provide successful applicants with up to 15 million euros for research and development.
“Rejoining the EIC venture capital program for R&D is a concrete step the current government can take to demonstrate its commitment to addressing the gender gap in healthcare and medicine by increasing funding opportunities in this underdeveloped field.”
Although the UK government has promised to use the strategy to “reset the dial on women’s health”, many femtech entrepreneurs feel that they are still being kept in the dark about the plan.
“From the pledge, it is unclear how the strategy will improve the overall state of women’s health,” said Jasmine Tagesson, co-founder and COO of Hormona. “There is so much to do and so many areas to improve.
“As a company that focuses on hormone health due to its massive impact on women’s overall health, we hope that the government doesn’t forget to look at the bigger, underlying issues that impacts women’s health.
“Hormone health is closely tied to the issues highlights, such as painful periods and postpartum issues and as such, we hope that the government will provide support for start-ups such as ourselves so that our efforts can help further research into different areas of women’s health.”
Dr Bryony Henderson, GP and associate medical director at Livi UK, said: “While this announcement is a positive step forward, it is essential that the strategy be comprehensive, adequately funded and inclusive of diverse perspectives and experiences.
“I urge the government to ensure that initiatives address the intersectional nature of women’s health, prioritise accessibility and equity and foster collaboration among healthcare providers.
“Long-term commitment and ongoing evaluation will be crucial to effectively address the complex and varied needs of women, while ensuring that every woman is given the fundamental right to make decisions about their body.”
She added: “In implementing the strategy, it is important to address gaps in the healthcare infrastructure, particularly in underserved areas. Ensuring equitable access to quality care, including specialised services and treatment options, is vital for improving health outcomes and reducing disparities.
“While research is essential, I would like to see preventative care and health promotion initiatives prioritised to empower women with knowledge and tools to maintain their reproductive health. This could include education on healthy lifestyle choices, regular screenings and preventive measures to reduce the risk of disease.”
You have until Friday to nominate your femtech company of the year.
The award is one of 10 featuring at Femtech World’s third annual awards event, which attracts entries from across the UK, EU and Europe.
The Company of the Year Award is for companies that have demonstrated exceptional leadership in tackling women’s health needs through groundbreaking products, services or platforms that are shaping the future of global femtech.
If your company is driving innovation, impact and growth in this space, this award was made for you.
About the sponsor: Femovate
The category is backed by Femovate, the global femtech incubator using design to fuel innovation across every stage of a woman’s health journey, from proactive prevention through to personalised treatment.
Femovate has invested over US$2 million in design capital, working side-by-side with founding teams to bring market-ready solutions to life.
The startups it supports have collectively raised US$120 million, launched 30 products, and secured seven FDA clearances.
Why enter?
The Femtech World Awards are free to enter.
Winners and shortlisted companies receive extensive coverage across all Femtech World platforms.
Winners will also receive a trophy and the opportunity to be featured in an interview for the publication.
Find out more about the Femtech World Award and enter here by 4pm BST on Friday 17.
Women with osteoporosis may be more likely to carry a gene linked to Alzheimer’s, according to new research.
Scientists found that APOE4, the most common genetic risk factor for Alzheimer’s, can weaken bone quality in women, even when standard scans appear normal.
The study, carried out by researchers at the Buck Institute for Research on Ageing in California, US, and UC San Francisco, suggests the gene may damage bone at a microscopic level long before any visible signs.
These changes can emerge as early as midlife and remain invisible to routine imaging tests used to assess bone strength.
The findings suggest a link between Alzheimer’s risk and skeletal health and could help pave the way for earlier detection of both conditions.
Professor Birgit Schilling, a senior author of the study, said: “What makes this finding so striking is that bone quality is being compromised at a molecular level that a standard bone scan simply will not catch.
“APOE4 is quietly disrupting the very cells responsible for keeping bone strong – and it is doing this specifically in females, which mirrors what we see with Alzheimer’s disease risk.”
Doctors have long observed that people with Alzheimer’s suffer higher rates of bone fractures, while osteoporosis in women is known to be one of the earliest predictors of the disease.
Now scientists believe they may have uncovered why.
Researchers led by Dr Charles Schurman carried out a detailed analysis of proteins in aged mouse bone and found that tissue was unusually rich in molecules linked to neurological disease, including those associated with Alzheimer’s.
In particular, long-lived bone cells known as osteocytes showed elevated levels of APOE, with levels twice as high in older female mice compared with younger or male animals.
Further experiments using genetically modified mice revealed that APOE4 had a strong and sex-specific impact on both bone and brain tissue.
The disruption at the protein level was even greater in bone than in the brain.
However, the bone structure itself appeared completely normal under scans.
Instead, the gene interfered with a key maintenance process inside bone cells, preventing them from repairing microscopic channels that keep bones strong and resilient.
When this process breaks down, bones become more fragile even if they look healthy on standard imaging.
These results suggest bone cells could potentially act as early biological warning signs of cognitive decline in women carrying APOE4.
Professor Lisa Ellerby, another senior author, said: “We think targeting these cells may open a new front in preserving bone quality in this population.”
Experts say the findings highlight the need to view the body as an interconnected system rather than treating diseases in isolation.
Dementia, of which Alzheimer’s is the most common form, remains one of the UK’s biggest health challenges.
Around 900,000 people are currently living with the condition, a figure expected to rise to 1.6 million by 2040.
It is already the leading cause of death, responsible for more than 74,000 deaths each year.
Health secretary Wes Streeting has relaunched England’s women’s health strategy, vowing to stop women being “gaslit” by doctors.
Speaking before publication of the renewed strategy, the health secretary said the NHS was “failing women” and set out measures to help them access the healthcare they need.
The government said the strategy would include a new standard of care to ensure women were offered pain relief for invasive procedures, such as fitting a contraceptive coil and hysteroscopies.
Feedback would be directly linked to provider funding through a new trial, giving women more power to affect change if they have a poor experience.
Action would also be taken to ensure women no longer face long waits for diagnoses for conditions such as endometriosis, which can take a decade to diagnose.
Streeting said: “[Women] have for so long been let down by a healthcare system that too often gaslights women, treating their pain as an inconvenience and their symptoms as an overreaction.
“Whether it’s being passed from one appointment to another for conditions like endometriosis and fibroids, or a lack of proper pain relief during invasive procedures, through to having to navigate symptoms for years before receiving a diagnosis, it’s clear the system is failing women.
“Women’s voices must be central to delivering effective, respectful and empathetic care. We need to hit medical misogyny where it hurts – the wallet.
“Today’s renewed strategy will tackle the issues women face every day and ensure no woman is left fighting to be heard.”
A report last month by the women and equalities committee found that gynaecological and menstrual health had not been “sufficiently prioritised” by the government.
MPs said parts of the 10-year women’s health strategy, launched in 2022 by the Conservatives, were at risk of being scaled back or discontinued under wider changes to the NHS.
These included initiatives that had reduced waiting lists and improved women’s access to healthcare, such as women’s health hubs.
Sarah Owen, chair of the committee and a Labour MP, said: “This would be a disaster for girls’ and women’s menstrual healthcare, when it is in dire need of more support.
“It is a national scandal that nearly half a million women are on hospital gynaecology waiting lists when there are effective treatments that could be administered in primary and community care, if only they could access them.”
The report said women faced “medical misogyny” and were left to “suck it up” and suffer in pain for years because of a lack of awareness of women’s health conditions.
A redesign of clinical pathways for some women’s health issues will aim to speed up diagnosis and treatment, and there will be a review of support for families who experience repeated baby loss.
The government also promised a “single referral point” to ensure women were directed to the right place the first time they sought help.
Dr Sue Mann, NHS England’s women’s health director, said too many women were dismissed for “serious symptoms” that affected every part of their lives.
“The renewed women’s health strategy will build significantly on the work the NHS has been doing to ensure women are heard and get the specialist care they need,” she said.
Women’s health groups cautiously welcomed the renewed strategy. Emma Cox, chief executive of Endometriosis UK, said decisive action would be vital to improve women’s healthcare in England.
Entrepreneur2 weeks agoThree sessions that show exactly where women’s health is heading in 2026
News4 weeks agoLuna and Kindbody partner to bring data-driven insight to women’s health and fertility care
News4 weeks agoFemtech World Awards announces deadline extension
Fertility4 weeks agoMenstruation costs £20,359 a lifetime, sparking calls for Government action
Menopause3 weeks agoCalifornia plans US$3.4m menopause care overhaul
News4 weeks agoHalogen Ventures surpasses 100 investments in female-founded startups
Menopause3 weeks agoWatchdog bans five ads for women’s heath claims
Pregnancy2 weeks agoHow NIPT has evolved and what AI NIPT means in 2026